ブログ

ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
Read time: 4 mins

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
Read time: 5 mins

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
Read time: 5 mins

Antibody-based therapies provide highly specific treatments for various diseases. Among these, VHH antibodies, derived from camelids, have garnered significant attention due to their unique properties. Unlike conventional antibodies, which are composed of two heavy and two light chains, VHH antibodies consist of a single variable heavy chain domain.

Jul 01, 2024
Read time: 6 mins

Cancer immunotherapy has emerged as a transformative approach in oncology, with immune checkpoint inhibitors (ICIs) at the forefront. ICIs work by blocking regulatory pathways in T cells that cancer cells exploit to evade immune detection.

Jun 28, 2024
Read time: 4 mins

The 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference 2024 was held in Boston, MA on 20-21 June, 2024. The event brought together academics and scientists from research institutes and biopharmaceutical companies to discuss the latest updates, challenges, and future directions in immuno-oncology research.

Jun 24, 2024
Read time: 2 mins

Welcometo Antibody Basics by Biointron,Part 10! In the last two episodes, we’ve discussed common targets for antibodydrugs: cancer and autoimmune diseases. In this episode, we’ll talk about infectiousdiseases. Infectious diseases are caused by pathogenic microorgan

Jun 21, 2024
Read time: 10 mins

Afucosylation of antigen-specific IgG can affect steady-state FcγRIII occupancy and effector activities in humans. DOI:10.1016/j.it.2022.08.001Afucosylated antibodies are characterized by the absence of fucose sugar residues on their Fc (fragment crystallizable) region. This modification has major

Jun 19, 2024
Read time: 3 mins

DOI:10.1016/j.apsb.2023.06.015Antibody-drug conjugates (ADCs) are a class of biopharmaceuticals designed to deliver cytotoxic drugs selectively to target cells, typically cancer cells, by exploiting the specificity of monoclonal antibodies (mAbs) for antigens expressed on the cell surface. The desig

Jun 17, 2024
Read time: 4 mins

DOI:10.1038/s41557-024-01507-y Antibody–drug conjugates (ADCs) have emerged as a revolutionary class of targeted cancer therapies, combining the specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. While traditional ADCs typ

Jun 14, 2024
Read time: 5 mins

Antibody Engineering & Therapeutics Europe 2024 was held in London, UK on 4-6 June, 2024. As Europe's leading antibody conference for accelerating next-generation antibodies to commercial success, topics discussed included:Emerging modalities: ADCs, degraders, and beyondFc

Jun 12, 2024
Read time: 4 mins

最新情報を入手したい場合、ご登録をよろしくお願いいたします。

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。